Cutaneous side-effects during therapy of melanoma by vemurafenib
Introduction. Vemurafenib is a selective inhibitor of serine-threonine kinase BRAF used in the treatment of advanced melanoma with BRAF mutation. Effectiveness of this drug was confirmed in a large clinical trial, which led to the increase of its usage. During treatment with vemurafenib, particul...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2015-06-01
|
| Series: | Przegląd Dermatologiczny |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Cutaneous-side-effects-during-therapy-of-melanoma-by-vemurafenib,56,25195,1,1.html |